{"id":452439,"date":"2021-03-08T08:03:14","date_gmt":"2021-03-08T13:03:14","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=452439"},"modified":"2021-03-08T08:03:14","modified_gmt":"2021-03-08T13:03:14","slug":"alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\/","title":{"rendered":"Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwalignl { text-align: left }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li class=\"bwalignl\"><b>First clinical trial of Aflibercept biosimilar to be completed in Korea<\/b><\/li>\n<li class=\"bwalignl\"><b>Supported by global formulation and process patents<\/b><\/li>\n<\/ul>\n<p>\n\u00a0\n<\/p>\n<p>DAEJEON, South Korea&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alteogen.com%2F&amp;esheet=52391379&amp;newsitemid=20210308005025&amp;lan=en-US&amp;anchor=Alteogen+Inc.&amp;index=1&amp;md5=129de2b373b5eef3f30c03f4527c227b\">Alteogen Inc.<\/a> (KOSDAQ:196170) announced that it has completed Phase 1 clinical trial of Eylea\u00ae Biosimilar (ALT-L9). The clinical trial was conducted at 4 major hospitals in Korea: Asan Hospital, Seoul National University Bundang Hospital, Samsung Seoul Hospital, and Severance Hospital. Alteogen has strengthened competitiveness through formulation patent registered in US, EU and Japan and filing of a process patent for PCT application.\n<\/p>\n<p>\nEylea\u00ae original product and Alteogen&#8217;s Eylea biosimilar (ALT-L9) were randomly assigned 1:1 to 28 patients with neovascular (wet) age-related macular degeneration; the study design was double blinded, active control, and parallel. No adverse drug-related reactions were observed in both groups and showed similar improvement effects in best corrected visual acuity (BCVA) and central subfield thickness (CST). In this phase 1 clinical trial, Alteogen confirmed the safety and efficacy of ALT-L9 were similar to that of Eylea\u00ae. Alteogen intends to prove the similarity of ALT-L9 with Eylea\u00ae through a registrational phase 3 clinical trial. The results from the phase 1 trial in Korea will support the design of the phase 3 trial and potentially provide a path to a shorter phase 3 trial.\n<\/p>\n<p>\nEylea\u00ae is a drug for the treatment of wet macular degeneration, one of the major senile blindness diseases, along with cataracts and glaucoma. Based on public reporting by Regeneron, the market size was about USD 4.947 Billion in 2020 in the United States alone, making this a blockbuster drug.\n<\/p>\n<p>\n\u201cAlteogen is uniquely positioned based on our patent position to launch a Eylea biosimilar upon substance patent expiration,\u201d said Dr. Soon Jae Park, Chief Executive Officer of Alteogen. \u201cOur patent position will give us potentially commercial first mover advantage.\u201d\n<\/p>\n<p>\nAltos Biologics Inc., a fully owned subsidiary of Alteogen will be responsible for all future clinical and commercial development.\n<\/p>\n<p><b>About Alteogen Inc.<\/b><\/p>\n<p>\nAlteogen Inc. is a South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as Antibody-Drug Conjugates (ADCs), biobetters, and biosimilars. Alteogen\u2019s portfolio includes clinical-stage long-acting therapeutic proteins and next-generation ADCs, developed by its proprietary NexP\u2122-fusion and NexMab\u2122 platform technology, respectively. It also developed a proprietary recombinant human hyaluronidase enzyme utilizing Hybrozyme\u2122 technology, which enables the large volume subcutaneous administration of drugs that are typically administered as an IV injection. The company was founded in 2008 and listed in KOSDAQ (196170.KQ).\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210308005025r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210308005025\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210308005025\/en\/<\/a><\/span><\/p>\n<p><b>For Alteogen \u2013 Media and Investors<br \/>\n<br \/><\/b>Arun Swaminathan, Ph.D.<br \/>\n<br \/>Chief Business Officer and Senior Vice President<br \/>\n<br \/>Phone: (609) 937 8767<br \/>\n<br \/>E-mail: <a rel=\"nofollow\" href=\"mailto:arun@alteogen.com\">arun@alteogen.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Asia Pacific South Korea<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Clinical Trials Research Science Pharmaceutical Optical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210308005025\/en\/863417\/3\/AlteoGen_Logo_Inc_viewimage.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients First clinical trial of Aflibercept biosimilar to be completed in Korea Supported by global formulation and process patents \u00a0 DAEJEON, South Korea&#8211;(BUSINESS WIRE)&#8211;Alteogen Inc. (KOSDAQ:196170) announced that it has completed Phase 1 clinical trial of Eylea\u00ae Biosimilar (ALT-L9). The clinical trial was conducted at 4 major hospitals in Korea: Asan Hospital, Seoul National University Bundang Hospital, Samsung Seoul Hospital, and Severance Hospital. Alteogen has strengthened competitiveness through formulation patent registered in US, EU and Japan and filing of a process patent for PCT application. Eylea\u00ae original product and Alteogen&#8217;s Eylea biosimilar (ALT-L9) were randomly assigned 1:1 to 28 patients with neovascular (wet) age-related macular degeneration; &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-452439","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients First clinical trial of Aflibercept biosimilar to be completed in Korea Supported by global formulation and process patents \u00a0 DAEJEON, South Korea&#8211;(BUSINESS WIRE)&#8211;Alteogen Inc. (KOSDAQ:196170) announced that it has completed Phase 1 clinical trial of Eylea\u00ae Biosimilar (ALT-L9). The clinical trial was conducted at 4 major hospitals in Korea: Asan Hospital, Seoul National University Bundang Hospital, Samsung Seoul Hospital, and Severance Hospital. Alteogen has strengthened competitiveness through formulation patent registered in US, EU and Japan and filing of a process patent for PCT application. Eylea\u00ae original product and Alteogen&#8217;s Eylea biosimilar (ALT-L9) were randomly assigned 1:1 to 28 patients with neovascular (wet) age-related macular degeneration; &hellip; Continue reading &quot;Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-08T13:03:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210308005025r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients\",\"datePublished\":\"2021-03-08T13:03:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\\\/\"},\"wordCount\":472,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210308005025r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\\\/\",\"name\":\"Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210308005025r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-03-08T13:03:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210308005025r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210308005025r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\/","og_locale":"en_US","og_type":"article","og_title":"Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients - Market Newsdesk","og_description":"Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients First clinical trial of Aflibercept biosimilar to be completed in Korea Supported by global formulation and process patents \u00a0 DAEJEON, South Korea&#8211;(BUSINESS WIRE)&#8211;Alteogen Inc. (KOSDAQ:196170) announced that it has completed Phase 1 clinical trial of Eylea\u00ae Biosimilar (ALT-L9). The clinical trial was conducted at 4 major hospitals in Korea: Asan Hospital, Seoul National University Bundang Hospital, Samsung Seoul Hospital, and Severance Hospital. Alteogen has strengthened competitiveness through formulation patent registered in US, EU and Japan and filing of a process patent for PCT application. Eylea\u00ae original product and Alteogen&#8217;s Eylea biosimilar (ALT-L9) were randomly assigned 1:1 to 28 patients with neovascular (wet) age-related macular degeneration; &hellip; Continue reading \"Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-08T13:03:14+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210308005025r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients","datePublished":"2021-03-08T13:03:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\/"},"wordCount":472,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210308005025r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\/","name":"Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210308005025r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-03-08T13:03:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210308005025r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210308005025r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/452439","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=452439"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/452439\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=452439"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=452439"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=452439"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}